$ 61.23
Key Takeaways
Risk factor
Very vulnerable to price shocks
Profitability factor
Greatly overvalued vs peers
About
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of IONS is 71 and suggests 17% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
